Hepatitis B virus mutations associated with antiviral therapy
- 18 April 2006
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 78 (S1) , S52-S55
Abstract
The hepatitis B virus (HBV) replicates via an error prone viral reverse transcriptase resulting in a large pool of quasispecies with mutations spread throughout the genome. During antiviral drug selection pressure (e.g., lamivudine, adefovir, or entecavir) HBV mutants are selected from the pre-existing pool of quasispecies and over time become the dominant species. Not all mutations result in replication competent virus as HBV has the added complexity of overlapping reading frames. The HBV polymerase (Pol) gene overlaps the hepatitis B surface antigen (HBsAg) in a frame-shifted manner with the result that drug-resistant mutations in the HBV Pol can directly impact on the nature of HBsAg and its function. HBV genomic databases have been established to monitor antiviral selected mutations and are useful in determining conserved residues, genotypic differences, polymorphisms, and the mutation profiles selected under different antiviral selection pressures. These HBV databases may aid in the development of new diagnostic reagents as well as the monitoring of polymerase and envelope mutations selected under different antiviral pressures. Antiviral drug resistant mutants emerge as a function of at least six factors: the viral mutation frequency, the intrinsic mutability of the antiviral target site, the selective pressure exerted by the drug, the magnitude and rate of virus replication, the overall replication fitness of the mutant, and the availability of replication space. Only a limited number of HBsAg mutations selected during antiviral treatment have been characterized and the diagnostic and public health implications of these mutations need further investigation. Clearly, improved treatment strategies are required urgently to prevent the continued selection of HBV drug-resistant mutants. J. Med. Virol. 78:S52–S55, 2006.Keywords
This publication has 14 references indexed in Scilit:
- Failure of the Lamivudine-Resistant rtM204I Hepatitis B Virus Mutants To Efficiently Support Hepatitis Delta Virus SecretionJournal of Virology, 2005
- Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to LamivudineAntimicrobial Agents and Chemotherapy, 2004
- The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In VitroJournal of Virology, 2003
- Week 48 Resistance Surveillance in Two Phase 3 Clinical Studies of Adefovir Dipivoxil for Chronic Hepatitis BHepatology, 2003
- Reduced Antigenicity of the Hepatitis B Virus HBsAg Protein Arising as a Consequence of Sequence Changes in the Overlapping Polymerase Gene That Are Selected by Lamivudine TherapyVirology, 2002
- Effects of extended lamivudine therapy in Asian patients with chronic hepatitis BGastroenterology, 2000
- Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patientsHepatology, 1999
- Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library.Proceedings of the National Academy of Sciences, 1996
- Natural History and Control of Perinatally Acquired Hepatitis B Virus InfectionDigestive Diseases, 1992
- Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles.Proceedings of the National Academy of Sciences, 1975